NCT01849666View on ClinicalTrials.gov

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Malignant Melanoma, Neoplasms

Interventions

DRUG

phenprocoumon

6 mg oral single dose

DRUG

vemurafenib

960 mg bid orally

Trial Locations (17)

1000

Brussels

2610

Wilrijk

2650

Edegem

9000

Ghent

28031

Madrid

28040

Madrid

28041

Madrid

28050

Madrid

31008

Pamplona

55101

Mainz

69120

Heidelberg

280146

Madrid

00180

Helsinki

1066 CX

Amsterdam

6229HX

Maastricht

3584 CX

Utrecht

08908

Barcelona

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01849666 - A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | Biotech Hunter | Biotech Hunter